Dosing Dynamics of Gemtuzumab in AML Treatment

This chapter explores the pharmacokinetics and pharmacodynamics of gemtuzumab, focusing on the critical calculations needed to avoid toxicities while treating acute myeloid leukemia (AML). It examines the implications of various dosing strategies based on clinical studies, particularly questioning the effectiveness of higher doses versus single dosing. The discussion also addresses the impact of patient demographics and historical treatment protocols on patient outcomes, encouraging a reevaluation of current standards of care.